Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The lancet. HIV
- Publicado em
- 6 mai 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
Eric G Meissner, Moti Ramgopal, Peter J Ruane, William Sanchez, Gordon Crofoot, Jean-Pierre Routy, Cynthia Brinson, Edwin DeJesus, Claudia T Martorell, Marcus Tellez et al.
Descritores MeSH
- HIV Infections
- Tenofovir
- Quinolones
- HIV-1
- Emtricitabine
- Anti-HIV Agents
- Adenine
- Heterocyclic Compounds, 4 or More Rings
- Amides
- Alanine
Veja também
Estudos relacionados
- Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study
- Ensaio de Fase 3 do Tratamento Semanal Oral de Islatravir- Lenacapavir para o HIV-1
- Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study
- Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes